Zuglimin 1000mg Tablet contains Imeglimin, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin acts by targeting mitochondrial bioenergetics to improve insulin sensitivity and enhance pancreatic beta-cell function, thereby contributing to improved glycemic control. Zuglimin is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise, to reduce elevated blood glucose levels. The 1000mg dosage is administered orally, with the frequency and duration of treatment determined by the healthcare provider based on individual patient needs and response. Clinical studies have demonstrated that Imeglimin effectively lowers HbA1c levels with a favorable safety profile, exhibiting minimal risk of hypoglycemia when used as monotherapy. Common adverse effects may include mild gastrointestinal disturbances such as nausea or diarrhea, which are generally transient. Caution is advised in patients with severe renal or hepatic impairment, and regular monitoring of renal function is recommended during therapy. Zuglimin should not be used in patients with type 1 diabetes or diabetic ketoacidosis. As with all antidiabetic agents, adherence to prescribed regimens and periodic assessment of glycemic status are essential to optimize therapeutic outcomes.